Drug Database
HU

human immunoglobulin (IV)

✓ Approved

Hualan Biological Engineering Co., Ltd. · 多克隆抗体 · 多克隆抗体

什么是 human immunoglobulin (IV)?

human immunoglobulin (IV) 是一种多克隆抗体,由Hualan Biological Engineering Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司Hualan Biological Engineering Co., Ltd.
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

human immunoglobulin (IV) 针对 6 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersImmunodeficiency✓ Approved
Skin and subcutaneous tissue disordersPurpuraPreclinical
Infections and infestationsSalmonellosisPreclinical
Infections and infestationsSepsisPreclinical
Infections and infestationsSystemic infectionPreclinical

注册免费账户还可查看另外 1 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedGastroenterology research2026-11-17

Pathological Complete Response in Stage IV Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer With Synchronous Liver Metastases After Conversion Therapy With SOX Plus Cadonilimab and Disitamab Vedotin.

Shi Xin X, Wang Wei Jun WJ, He Ke Ji KJ, Wang De Chen C et al.

Initially unresectable stage IV gastric cancer is usually treated with systemic therapy. Conversion surgery may be considered in selected patients after a substantial response. Pathological complete response (pCR) in the resected gastric primary and lymph nodes after such treatment is uncommon. We report the case of a 51-year-old male diagnosed with gastric adenocarcinoma (cT3NxM1, clinical stage IV) with synchronous liver metastases. The tumor was human epidermal growth factor receptor 2 (HER2)-positive (3+), proficient in mismatch repair (pMMR), with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of 30. After three cycles of oxaliplatin + S-1 (SOX) combined with cadonilimab, and disitamab vedotin, computed tomography imaging demonstrated marked tumor regression with nearly complete resolution of liver metastases. The patient underwent radical distal gastrectomy with D2 lymphadenectomy. Postoperative pathology revealed tumor regression grade (TRG) 0-a complete pathological response-with all 33 lymph nodes negative for carcinoma and all surgical resection margins clear (R0). Intraoperative ultrasound confirmed no residual liver metastases. This case illustrates complete pathological regression in the examined gastric and nodal specimens after SOX, cadonilimab, and disitamab vedotin, the patient achieved a pathological complete remission after conversion surgery, accompanied by significant radiological regression of liver lesions. However, it also raises a series of questions for further consideration, such as whether conversion surgery can provide additional benefits after achieving deep tumor regression, the safety of combination therapy, and how to select appropriate candidates for surgery.

PMID 43042191
阅读全文 →
PubMedJournal of hematology2026-11-17

Measles Pneumonia After Allogeneic Hematopoietic Stem Cell Transplantation.

Jimenez-Ochoa Marco Alejandro MA, Contreras-Serratos Maria Margarita MM, Urbina-Escalante Elizabeth E, Pardo-Escobedo Maria Gabriela MG et al.

Measles is a highly contagious viral infection that is rarely reported after allogeneic hematopoietic stem cell transplantation (HSCT), with only a limited number of cases described in the literature. We report the case of a 46-year-old woman who developed laboratory-confirmed measles complicated by atypical pneumonia 3 years after human leukocyte antigen (HLA)-identical sibling allogeneic HSCT for acute lymphoblastic leukemia. Her post-transplant course had been complicated by steroid-refractory chronic graft-versus-host disease (GVHD), successfully treated with ruxolitinib, which had been discontinued only a few months before presentation. She was admitted with fever, severe odynophagia, and diffuse oral mucosal erythema, leading to an initial diagnosis of chronic GVHD flare and treatment with corticosteroids and empirical antimicrobials. During hospitalization, she rapidly developed hypoxemic respiratory failure and a characteristic cephalocaudal maculopapular rash. Reverse transcription polymerase chain reaction (RT-PCR) of a throat swab confirmed measles virus infection. Corticosteroids were discontinued, and the patient received supportive care and intravenous immunoglobulin (IVIG), with complete clinical and radiologic recovery. Notably, despite adequate quantitative immune reconstitution, including preserved CD4+ and CD8+ T-cell counts and normal immunoglobulin levels, she remained susceptible to measles because she was not yet eligible for measles-mumps-rubella (MMR) vaccination according to current post-transplant recommendations. This case highlights the diagnostic challenge of distinguishing measles from chronic GVHD in transplant recipients, emphasizes that quantitative immune recovery does not necessarily reflect pathogen-specific immunity, and underscores the importance of maintaining a high index of suspicion and performing early molecular testing during community outbreaks.

PMID 43042413
阅读全文 →
PubMedCureus2026-11-17

Left Eye Ocular Tuberculosis in an Immunocompromised Patient: A Diagnostic Dilemma.

Ibrahim Farah Ibtisam FI, Tuan Jaffar Tengku Norina TN, Tai Evelyn E

This case report discusses a 46-year-old male patient with a history of recurrent tuberculosis (TB) and human immunodeficiency virus (HIV), who presented with progressive left eye blurring of vision over two weeks, with eye redness and pain while hospitalized for disseminated cutaneous sporotrichosis. Initial investigations revealed a positive cytomegalovirus polymerase chain reaction test (CMV PCR) and tuberculin test, leading to a diagnosis of left eye CMV retinitis. Despite treatment with IV ganciclovir, the patient's ocular condition worsened, prompting a revised diagnosis of presumed ocular TB (OTB). The patient was started on intensive anti-TB therapy (ATT), and rapid regression of the choroidal lesion size and vitritis was observed two weeks after the commencement of ATT. The case highlights the diagnostic challenges and management complexities in patients with coexisting infections.

PMID 43042083
阅读全文 →
PubMedEClinicalMedicine2026-11-17

Two-step deep learning for candidemia prediction using time-series electronic health record data from the USA: a model development and validation study.

Yoshida Hisato H, Adelman Max W MW, Rasmy Laila L, Ifiora Francis F et al.

Candidemia is a rare, life-threatening bloodstream infection that is difficult to predict using conventional risk-stratification methods, often delaying empiric antifungal therapy. We developed a deep-learning model (PyTorch_EHR) to predict 7-day candidemia risk with retrospective electronic health record data from two large cohorts (Houston Methodist Hospital System [HMHS], USA [6/2016 to 6/2023] and MIMIC-IV, version-3.1, Beth Israel Deaconess Medical Centre, USA [2008 to 2022]), including adult inpatients who underwent at least one blood culture. Model performance was compared with logistic regression (LR), LightGBM, and intensive care unit candidemia scores. We implemented a two-step prediction framework integrating candidemia and 30-day mortality risk models to inform empiric antifungal decision-making. Among 213,404 and 107,507 patients in the HMHS and MIMIC-IV cohorts, candidemia occurred in fewer than 1% (851/213,404 [0.4%] and 634/107,507 [0.6%], respectively). PyTorch_EHR outperformed LR, LightGBM, and existing candidemia scores, particularly in terms of area under the precision-recall curve (AUPRC) in HMHS and MIMIC-IV (all p < 0.05). By integrating 30-day mortality risk, the two-step framework identified an additional 20 and 28 candidemia cases beyond the one-step model, increasing coverage to 60.8% [121/199] and 46.3% [68/147] in HMHS and MIMIC-IV, respectively. Many candidemia cases identified by the two-step framework did not receive empiric antifungal therapy and had high 30-day mortality (39.4% [41/104] in HMHS; 61.9% [39/63] in MIMIC-IV). A two-step deep-learning framework integrating candidemia and mortality risk may support early identification of high-risk patients and facilitate timely empiric antifungal therapy. Prospective studies are warranted to confirm the findings. NIH/NIAID.

PMID 43042024
阅读全文 →
PubMedResearch (Washington, D.C.)2026-11-17

Magneto-Piezoelectric S-Scheme Nanozymes Reprogram Bacterial Energy Metabolism for Immune-Activated Pneumonia Therapy.

Zhang Shuai S, Qu Huanran H, Liu Ruocan R, Shao Shiyang S et al.

Chronic pulmonary infections caused by multidrug-resistant Pseudomonas aeruginosa (MDR-PA) biofilms remain difficult to eradicate because biofilm protection limits antibacterial efficacy and promotes immune evasion. Here, we develop an S-scheme heterojunction nanozyme, NEF/BMO@PVP (NBP), that integrates piezoelectric catalysis (PCT), nanozyme catalysis (NCT), and magnetothermal therapy (MHT) for non-antibiotic pneumonia treatment. Under ultrasound and alternating magnetic field stimulation, piezoelectric polarization, interfacial charge transfer, enzyme-mimetic catalysis, and magnetothermal acceleration cooperatively amplify reactive oxygen species (ROS) generation. NBP-induced oxidative stress was accompanied by disruption of bacterial metabolic homeostasis, including impaired coenzyme synthesis, respiratory electron transport, and adenosine triphosphate (ATP) production, together with alterations in GacS/GacA-associated regulatory factors, which may contribute to reduced biofilm formation and virulence-associated behaviors. In infected mice, NBP suppresses bacterial proliferation, enhances macrophage-mediated antigen presentation, alleviates T and B cell suppression, and reduces myeloid-derived suppressor cell infiltration, thereby restoring antibacterial immunity. NBP further activates memory T/B cell responses and increases pathogen-specific immunoglobulin G and immunoglobulin M production, providing protection against infection recurrence. This work establishes a magneto-piezoelectric S-scheme strategy that couples multichannel ROS amplification with bacterial energy-metabolism disruption and durable antibacterial immune activation.

PMID 43041565
阅读全文 →
PubMedFrontiers in medicine2026-11-17

Age-related differences in postoperative pain after single-port access adnexal laparoscopy: a three-arm analgesic strategy comparison.

Paik E Sun ES, Yu Minjung M, Kang Jiyeon J, Kang Jun-Hyeok JH

This study evaluated age-related differences in postoperative pain and analgesic requirements after single-port access (SPA) laparoscopy for adnexal disease under three analgesic regimens. This retrospective cohort study included 470 patients stratified into: <40 years (n = 257), 40-55 years (n = 138), and >55 years (n = 75). Patients received continuous wound infiltration (CWI) alone, intravenous patient-controlled analgesia (IV PCA) alone, or combined CWI + IV PCA. NRS pain scores at 6, 12, 24, and 48 h were the primary outcomes. Multivariable regression adjusted for analgesic regimen, surgery type, and body mass index, with additional adjustment for endometriosis in sensitivity analysis. Unadjusted NRS scores did not differ among age groups. Rescue nonsteroidal anti-inflammatory drug use was higher in patients aged <40 years at 0-6, 6-12, and 24-48 h. After adjustment, patients aged <40 years had significantly higher NRS scores at 24 h (β = 0.276, p = 0.046). Combined CWI and IV PCA was associated with the lowest postoperative pain scores across age groups; however, a formal age × treatment interaction was not statistically significant. Sensitivity analysis yielded consistent findings. Younger age (<40 years) was independently associated with modestly higher postoperative pain at 24 h after SPA adnexal laparoscopy, although this difference was below the minimal clinically important difference. These findings may inform individualized analgesic planning, pending confirmation in prospective studies.

PMID 43042103
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多human immunoglobulin (IV)